NOV-205 is an injectable, small-molecule proprietary formulation of oxidised glutathione and inosine that acts as a hepatoprotective agent with immunomodulating and anti-inflammatory properties. The ongoing US Phase 2
Oramed Pharma said that the Phase 2b trial is a randomised, double-blind, placebo-controlled, multi-centered study, that primary evaluated the safety, and tolerability of Oramed’s oral insulin delivery technology.
The Collaborative Research Initiative will be a strategic expansion of the company’s ‘Project Boveri: Find the Cure,’ adding the ability to monitor hourly chromosome aneuploidy progression. ChromoCure’s technology
Dara BioSciences said that the study will enroll approximately 75 volunteers and will be conducted at Quintiles’ Overland Park facility. The study’s main objectives are to determine the
Alogliptin (once daily dosing) was discovered by Takeda’s wholly-owned subsidiary Takeda San Diego and is a member of the dipeptidyl peptidase IV (DPP-4) inhibitors class. DPP-4 selectively metabolizes
Velaglucerase alfa is manufactured in Shire’s facility in Cambridge MA, which was inspected and approved by the FDA for the commercial production of VPRIV. VPRIV was approved by
Uveitis is an inflammatory condition of the internal structures of the eye that can lead to cataract, glaucoma, scarring, pain, photophobia, and even permanent loss of vision when
Quintiles said that the new Phase I unit is expected to draw on the existing experience of Quintiles staff in India, including their cardiology group, the expertise of
The acquisition of ‘i-pill’ will strengthen Piramal’s OTC portfolio which has consumer brands such as Lacto Calamine skin care range, Supractiv Complete, Saridon and Polycrol antacid. ‘i-pil’ is
Cell Therapeutics develops, acquires, and commercialises oncology products for cancer treatment. The complaint charges Cell Therapeutics and certain of its officers and executives with violations of the Exchange
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.